Loading...
CD123 as a Biomarker in Hematolymphoid Malignancies: Principles of Detection and Targeted Therapies
SIMPLE SUMMARY: CD123 is overexpressed in multiple hematologic malignancies. Advances in CD123-targeted therapies over the past decade have positioned this molecule as an integral biomarker in current practice. This review provides an overview of CD123 biology and in-depth discussion of clinical lab...
Saved in:
| Published in: | Cancers (Basel) |
|---|---|
| Main Authors: | , , , |
| Format: | Artigo |
| Language: | Inglês |
| Published: |
MDPI
2020
|
| Subjects: | |
| Online Access: | https://ncbi.nlm.nih.gov/pmc/articles/PMC7690688/ https://ncbi.nlm.nih.gov/pubmed/33113953 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3390/cancers12113087 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|